Location
Headquarters: Melbourne, Victoria, Australia, Oceania
Region: Victoria
Country: AU
Continent: Oceania
About
CSL is a global biotechnology company composed of CSL Behring, CSL Seqirus, and CSL Vifor, delivering lifesaving medicines and vaccines across more than 100 countries. The company focuses on rare and serious diseases, plasma-derived and recombinant therapies, influenza vaccines, and therapies for iron deficiency and nephrology, with R&D and manufacturing capabilities spanning multiple continents. Since 1916, CSL has combined commercial strength with research-driven innovation to improve patient outcomes worldwide. Its three business units concentrate on plasma/biologics therapy, vaccines, and iron/Kidney health, affirming CSL’s commitment to public health and life-saving care.
CSL is a global biotechnology company that develops and manufactures plasma-derived therapies, vaccines, and treatments for kidney and iron deficiency disorders. Operating through subsidiaries CSL Behring, CSL Seqirus, and CSL Vifor, the company serves patients in over 100 countries with a focus on rare and serious diseases.
CSL Limited
1916
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
750000000
over-1b
ipo
CSLLY
otcmkts
Investors
Leadership
Sandro Krug — Human Resources Director Intercontinental Commercial Operations
Joy Linton — Chief Financial Officer
Jeffrey Ball — SVP Enterprise EHS, Sustainability & Strategy Realization
Paul Perreault — Chief Executive Office and Managing Director
Peter Turner — President of CSL Behring
Galit Gonen-Cohen — SVP, Chief IP officer
Megs Shah — Global Head of Data and Analytics Capability for Commercial
Technology Stack
Products
CSL Behring Biotherapies: Biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders, and Alpha 1 Antitrypsin Deficiency.
CSL Seqirus Influenza Vaccines: Influenza vaccines developed to protect public health by preventing flu infections and reducing disease burden.
CSL Vifor Therapies for Iron Deficiency and Nephrology: Therapies addressing iron deficiency and kidney-related diseases, including treatments for dialysis and rare kidney conditions.
HEMGENIX® Gene Therapy for Hemophilia B: A gene therapy treatment designed to provide a long-term solution for patients with hemophilia B by reducing the need for regular infusions.
Funding rounds
ACQUISITION · 18800000000 · (2013-12-01T00:00:00)
POST_IPO_EQUITY · 111000000 · (2004-02-01T00:00:00)
IPO · 220000000 · (1994-06-01T00:00:00)
Connect
Connect
Open positions(3)
- ECP Co-op - US Graphic Designer Co-OpInternshipWork from OfficeAmericas, US-PA, King of Prussia, CSL Behring
- ECP Co-op - Global Graphics Designer Co-OpInternshipWork from OfficeAmericas, US-PA, King of Prussia, CSL Behring
- Senior Clinical ScientistFull-timeHybridAmericas, US-PA, King of Prussia, CSL Behring